News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
An accomplished R&D leader and champion of the application of AI to drug discovery
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Subscribe To Our Newsletter & Stay Updated
